KRAS and cancer: There have been several reports suggesting RAF dimer or pan‐RAF inhibitor in combination with MEK inhibitor may be a strategy to target K‐RAS‐mutated cancers (Lamba et al., 2014; Whittaker et al., 2015; Yen et al., 2018).